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Abstract
Background: The serotonin receptor 2A (HTR2A) has been described as an im-
portant facilitation mediator of spinal nociceptive processing leading to central sen-
sitization (CS) in animal models of chronic pain. However, whether HTR2A single 
nucleotide variants (SNVs) modulate neuropathic pain states in patients has not been 
investigated so far. The aim of this study was to elucidate the potential association 
of HTR2A variants with sensory abnormalities or ongoing pain in neuropathic pain 
patients.
Methods: At total of 240 neuropathic pain patients and 253 healthy volunteers 
were included. Patients were phenotypically characterized using standardized quan-
titative sensory testing (QST). Patients and controls were genotyped for HTR2A  
g.-1438G > A (rs6311) and c.102C > T (rs6313). Genotype-related differences in 
QST parameters were assessed considering QST profile clusters, principal soma-
tosensory components and sex.
Results: There was an equal distribution of rs6313 and linked rs6311 between pa-
tients and controls. However, the rs6313 variant was significantly associated with a 
principal component of pinprick hyperalgesia and dynamic mechanical allodynia, 
indicating enhanced CS in patients with sensory loss (−0.34 ± 0.15 vs. +0.31 ± 0.11 
vs., p < .001). In this cluster, the variant allele was also associated with single QST 
parameters of pinprick hyperalgesia (MPT, +0.64 ± 0.18 vs. −0.34 ± 0.23 p = .002; 
MPS, +0.66 ± 0.17 vs. −0.09 ± 0.23, p = .009) and ongoing pain was increased by 
30%.
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1 |  INTRODUCTION
Neuropathic pain arises after lesion or disease of the so-
matosensory system (https://www.iasp-pain.org). It is char-
acterized by multiple somatosensory phenomena including 
positive signs like ongoing or evoked pain and negative signs 
like hypoesthesia (Baron et  al.,  2012; Maier et  al.,  2010). 
These signs can be attributed to interaction of several patho-
physiological mechanisms, that is, an imbalance of periph-
eral or central sensitization (CS) and inhibitory mechanisms. 
Peripheral sensitization results from increased excitability of 
primary afferents (clinical correlate: localized heat hyperal-
gesia). CS (clinical correlates: dynamic mechanical allody-
nia, pinprick hyperalgesia) is caused by increased excitability 
of wide-dynamic-range neurons in the dorsal horn of the spi-
nal cord (Baron et al., 2010).
Spinal nociceptive processing is modulated by facilita-
tory and inhibitory descending pathways originating in the 
brainstem. While increased descending inhibition protects 
the transition from acute to chronic pain, increased de-
scending facilitation might promote chronification (Ossipov 
et  al.,  2010). Among others, descending control is medi-
ated via serotonergic (5-HT) pathways (Millan, 2002). The 
5-HT2 receptor (HTR2) is thought to play a crucial role in 
spinal pain modulation. While HTR2C might be involved 
in antinociceptive pathways, HTR2A is assumed to play a 
pronociceptive role resulting in increased spinal nociceptive 
transmission and CS (Aira et al., 2010; Rahman et al., 2011; 
Van Steenwinckel et al., 2009). This is supported by HTR2A 
protein expression being positively correlated with mechani-
cal hypersensitivity in an animal model of HIV-induced neu-
ropathy (Van Steenwinckel et  al., 2008). While mechanical 
hyperalgesia was absent in HTR2A knock-out mice, it was 
reduced in heterozygous mice. Moreover, pain-related be-
haviour signs of mechanical hyperalgesia or allodynia are 
attenuated by HTR2A antagonism in other animal models 
of neuropathic pain (Cervantes-Durán et al., 2016; Nitanda 
et al., 2005; Sasaki et al., 2006).
Modulation of the HTR2A functionality and activity is 
poorly understood, although the association of single nucle-
otide variants (SNVs) in HTR2A, that is, rs6311 and rs6313, 
was investigated within studies concerning depression and 
chronic pain. HTR2A variants were reported to be associated 
with a higher depression score in female chronic pain patients 
(Lebe et  al.,  2013), higher postoperative analgesic require-
ments (Aoki et al., 2010), increased pain intensity in irritable 
bowel syndrome (Pata et al., 2004) and chronic widespread 
pain (Nicholl et al., 2011). A study investigating the role of 
HTR2 variants on neuropathic pain relief during escitalo-
pram treatment showed no association of HTR2A rs6314 but 
of HTR2C rs6318 with better pain relief (Brasch-Andersen 
et al., 2011).
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Conclusions: The specific association of the rs6313 variant with pinprick hyperalge-
sia and increased levels of ongoing pain suggests that the HTR2A receptor might be 
an important modulator in the development of CS in neuropathic pain.
Significance: This article presents new insights into serotonin receptor 2A-mediating 
mechanisms of central sensitization in neuropathic pain patients. The rs6313 variant 
allele was associated with increased mechanical pinprick sensitivity and increased 
levels of ongoing pain supporting a contribution of central sensitization in the genesis 
of ongoing pain providing a possible route for mechanism-based therapies.
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In previous studies, we showed an association of SNVs 
in TRPV1, transient receptor potential ankyrin 1 (Binder 
et  al.,  2011) and sigma-1 receptor (SIGMAR1; Sachau 
et al., 2019) with changes in thermal and mechanical sensitiv-
ity. The contribution of HTR2A variants to neuropathic pain 
susceptibility (ongoing pain) and somatosensory sensitivity 
profiles (evoked pain) is largely unknown.
Thus, we aimed to compare genotype distribution of SNVs 
in HTR2A between neuropathic pain patients and healthy 
volunteers. We analysed the impact of HTR2A variants on 
the somatosensory function of neuropathic pain patients as-
sessed by standardized quantitative sensory testing (Binder 
et al., 2011; Rolke et al., 2006).
2 |  METHODS
2.1 | Study populations
A total of 240 patients (mean age 54.52 ± 13.95 years, range 
19–84 years; 128 females, 112 males), all white Caucasians, 
with chronic neuropathic pain syndromes collected within 
the German Research Network on Neuropathic Pain (DFNS) 
were included into the study. This study cohort was the same 
as in previous studies by Binder et  al.  (2011) and Sachau 
et al. (2019). The patients suffered from a variety of neuro-
pathic pain syndromes or pain syndromes with neuropathic 
features, that is, polyneuropathy (PNP; n  =  65), post-her-
petic neuralgia (PHN; n = 21), peripheral nerve injury (PNI; 
n = 27), complex regional pain syndrome (CRPS; n = 68), 
trigeminal neuropathy (TGN; n  =  35), central pain (CP; 
n = 11) and other neuropathies (n = 13; Binder et al., 2011). 
Although CRPS type 1 has recently been defined as nociplas-
tic pain (nerve lesion not demonstratable), CRPS was con-
sidered as pain syndrome with neuropathic features in this 
study as both types, CRPS type I and type II, share similar 
sensory symptoms and signs (Gierthmühlen et  al.,  2014). 
For comparison, 253 healthy German volunteers (mean age 
34.12 ± 7.01 years, range 27–67; 172 females, 81 males), all 
white Caucasians, were collected at the University Hospital 
Schleswig-Holstein (Gierthmühlen et al., 2015).
All subjects gave their written informed consent. The study 
was approved by the Ethics Committee of the Medical Faculty 
of the Kiel University and Ethic Committees of the participat-
ing DFNS centres (AZ: 114/05, AZ 131/05, B204/04) and was 
performed according to the declaration of Helsinki.
2.2 | Phenotypical characterization 
(quantitative sensory testing)
All patients were phenotypically characterized using standard-
ized quantitative sensory testing (QST), a validated test battery 
established by the DFNS (www.neuro.med.tu-muenc hen.de/
dfns/) to determine somatosensory function and symptoms of 
pain (Magerl et al., 2010; Rolke et al., 2006). Accordance with 
the protocol was ensured by regular quality control (Vollert 
et  al.,  2015, 2016). This QST battery consists of seven tests 
measuring 13 sensory parameters. Briefly, thermal detection 
thresholds for the perception of cold (CDT) and warm (WDT), 
thermal pain thresholds for cold (CPT) and heat (HPT), thermal 
sensory limen (TSL), paradoxical heat sensation (PHS), me-
chanical detection thresholds for touch (MDT) and vibration 
(VDT), mechanical pain threshold (MPT), a stimulus–response 
function for pinprick sensitivity (MPS) and dynamic mechani-
cal allodynia (DMA), pain summation to repetitive pinprick 
stimuli (wind-up ratio; WUR) as well as blunt pressure pain 
threshold (PPT) were assessed in the area of maximum pain 
and a contralateral mirror image control area. Patient data were 
included in the study analysis, if at least results of 12 of 13 QST 
tests were available.
2.3 | Selection of candidate SNVs
Two SNVs in HTR2A g.-1438G > A (rs6311) and c.102C > T 
(rs6313) were selected due to (a) the high frequency of the 
minor allele, (b) already described associations to various 
disease stages and (c) potential alteration of transcription 
(Parsons et al., 2004; Smith et al., 2013).
2.4 | Genotype analysis
Whole-genomic DNA was extracted from venous blood 
samples obtained from patients and volunteers using the 
Qiagen Gentra Puregene Blood Kit (Qiagen). The final con-
centration of genomic DNA was estimated spectrophoto-
metrically (Binder et al., 2011). Genotyping of the selected 
SNVs was performed by pyrosequencing according to proto-
cols provided by the manufacturer on a PSQ HS96 platform 
(HS 96 system, Qiagen). For PCR, 1  µl gDNA was added 
to 25  µl mastermix containing PCR buffer (500  mmol/L 
KCl, 200  mmol/L Tris-HCl; pH 8.4), 50  mmol/L MgCl2, 
10 mmol/L dNTPs (2.5 mmol/L each), forward and reverse 
primer each 10 µmol/L (one of them biotinylated for pyrose-
quencing analysis), 75 U Taq polymerase (500  U/µL) and 
ultra-pure water. All reagents, except the primers (Sigma-
Aldrich), were obtained from Thermo Fisher Scientific. For 
each PCR, two negative controls (NTC) were included. PCR 
amplification consisted of initial denaturation at 94°C for 
4 min, 50 cycles containing 30 s at 94°C, 30 s annealing at 
63° and 30  s elongation at 72°C. Final elongation was ex-
ecuted for 7 min at 72°C. Pyrosequencing was conducted as 
previously described (Bruckmueller et al., 2015). Primer se-
quences are available on request.
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2.5 | Statistical analysis
Statistical analysis was performed by comparing frequen-
cies of selected SNVs between neuropathic pain patients 
and healthy controls as well as with regard to associations of 
SNVs to QST parameters in patients.
Z-scores of the respective patient QST values (except for 
DMA and PHS) were available from a previous study (Binder 
et al., 2011). Normalization of z-scores accounts for differ-
ences in sex, age and specific body region, allowing direct 
comparison with values of healthy controls. Z-scores of zero 
represent the mean of healthy controls, while z-scores above 
‘0’ indicate a gain of function (hyperalgesia) and z-scores 
below ‘0’ indicate a loss of function (hypoesthesia and hy-
poalgesia). Abnormal values were determined according to 
reference data, that is, z values below −1.96 were considered 
as abnormal loss and z values above 1.96 as abnormal gain of 
function (95% confidence interval of relative reference data; 
Maier et al., 2010; Rolke et al., 2006). DMA and PHS, ab-
sent under physiological conditions, were given with original 
values (DMA: 0–100 numeric rating scale; PHS: numbers of 
PHS, 0–3). Patients were subdivided into two main clusters 
following a previous analysis (Binder et  al.,  2011). These 
clusters are represented by considerably different somatosen-
sory QST z-profiles. Cluster 1 included a group of patients 
with mainly preserved sensory function, whereas cluster 2 
patients were characterized by a relative loss of small and 
large fibre function.
The two selected genetic variants in HTR2A were tested 
for Hardy–Weinberg equilibrium with chi-squared test 
and for linkage disequilibrium using Haploview (Barrett 
et  al.,  2005). Statistical analysis was performed comparing 
all three genotypes as well as by use of the dominant ge-
netic model for each SNV comparing wild-type carriers to 
carriers of at least one variant allele. Allele distribution of 
selected variants of pain patients was compared to healthy 
controls using chi-squared test. Minor allele frequencies of 
patients and controls were compared to published data of the 
1000 Genomes Project (1000 Genomes Project Consortium 
et  al.,  2015; https://www.ncbi.nlm.nih.gov/snp/) by use of 
chi-squared test.
To reduce the number of sensory components (QST val-
ues) to the principal structure of somatosensory perception 
in neuropathic pain patients, principal component analy-
sis (PCA) was performed as described elsewhere (Sachau 
et al., 2019).
Mean values of the QST parameters (z values or log trans-
formed for DMA) relevant for each PCA were calculated. 
Analysis of variance was calculated on these principal so-
matosensory components (mean values for the parameters 
describe above) using three-way ANOVAs with the factors 
‘homozygous wild-type versus heterozygous versus homozy-
gous variant carrier’, ‘cluster 1 versus cluster 2’ and ‘male 
versus female’ and post hoc contrasts to identify the poten-
tial presence of heterozygous effects. Additional three-way 
ANOVAs were calculated with the factors ‘homozygous wild-
type versus variant carriers’ (dominant genetic model), ‘clus-
ter 1 versus cluster 2’ and ‘male versus female’ to disclose 
the impact of the variant allele and potential interactions. The 
influence of the SNVs on each principal component was also 
calculated for the different patient groups, that is, for all pa-
tients, for cluster 1, for cluster 2 and for male or female sex, 
respectively, using one-way ANOVA. To control for multiple 
comparison, p values were Bonferroni adjusted considering 
the number of different principal components (resulting in 
p < .0125 for four PCAs and p < .025 for a significant trend 
(α = 0.10), see Section 3).
In a second step, the genotype influence of each SNV on 
single QST parameters (z-scores) within the patient cohort 
was investigated, considering only the QST parameters of the 
significant principal somatosensory component. One-way 
ANOVA for the respective QST parameters, sex and vari-
ant was performed as described above. In case of significant 
Levene test for equality of variances (<0.05), Welch's t test 
was used. Differences of DMA and PHS were calculated 
with Kruskal–Wallis test. In case of significant differences 
in z values, a gene-dose effect for the three genotypes was 
calculated using a linear regression model.
Differences in frequencies of abnormal QST values 
were assessed with chi-squared test and Fisher's exact test 
for n < 5. For this calculation, QST values were encoded as 
nominal values with three categories (within normal range; 
abnormal loss; abnormal gain of somatosensory function). 
PHS and DMA were encoded as dichotomized variables (ab-
sent = normal; present = abnormal). Differences were ana-
lysed (a) within the entire patient cohort and (b) separately 
within cluster 1 and 2 patients. Analysis was also performed 
for male and female patients separately.
To control for multiple comparison, p values were 
Bonferroni adjusted considering the number of parameters 
within the significant principal component (resulting in 
p < .0167 for the three parameters of PC2 and p < .033 for a 
significant trend (α = 0.10), see Section 3).
Finally, a modified three-cluster analysis was used to sub-
group patients based on their QST profiles as described more 
recently (Baron et al., 2017). These clusters have been shown 
to be similar to mechanistic surrogate models of neuropathy 
(Vollert et al., 2018). Cluster SL was characterized by a sen-
sory loss (loss of small and large fibre function with PHS), 
cluster TH showed a thermal hyperalgesia (preserved sensory 
function in combination with heat and cold hyperalgesia and 
mild DMA) and cluster MH showed a mechanical hyperal-
gesia (loss of small fibre function with pinprick hyperalgesia 
and DMA). The frequency of each genotype in the three clus-
ters was calculated by use of the chi-squared test. Due to the 
small sample size, calculation of the genotype influence of 
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each SNV on the PCs and single QST parameters (see above) 
was not performed for the three clusters.
Finally, the same models of analysis described above were 
also used to analyse the magnitude of ongoing pain. To test 
whether an association of the variant allele with the relevant 
principal somatosensory component predicts the magnitude 
of ongoing pain was tackled with additional analysis using 
chi square and correlation analysis.
All statistical evaluations were performed using statistical 
software SPSS 23.0 (IBM).
3 |  RESULTS
Due to technical issues, that is, no clear genotyping results, 
six patients were excluded from further analysis. Of the re-
maining 234 patients, 117 were characterized by mainly pre-
served somatosensory function (cluster 1 according to Binder 
et al., 2011) and 117 by relative loss of small and large fibre 
function (cluster 2). According to the modified three-cluster 
analysis (Baron et al., 2017), 120 patients were characterized 
by preserved function and thermal hyperalgesia (cluster TH), 
which mostly contained the cluster 1 cases (n = 92). In all, 81 
patients were characterized by sensory loss with mechanical 
hyperalgesia (cluster MH) and 33 patients by sensory loss 
without hyperalgesia (cluster SL), each mostly containing 
cluster 2 cases (n = 61 and n = 28, respectively). Patients 
characteristics are shown in Table 1 and comparison of two-
cluster versus three-cluster solution in Figure 1.
3.1 | HTR2A genotype distribution between 
patients and controls
Due to poor genotyping results, 5 healthy controls were ex-
cluded for HTR2A rs6311 and 14 for rs6313. Frequencies 
T A B L E  1  Demographic data of patients
All neuropathic 
pain patients Cluster 1 Cluster 2 Cluster SL Cluster TH Cluster MH















Females (%) 52.6 55.6 49.6 39.4 61 7 44.4
Males (%) 47.4 44.4 50.4 60.6 38.3 55.6
Disease duration 
(months)
37.87 ± 63.96 40.26 ± 79.31 35.82 ± 47.43 53.60 ± 54.54 32.22 ± 56.05 38.22 ± 78.45
Mean pain intensity 
(0–10 Likert-Scale 
NRS)
5.90 ± 2.19 5.71 ± 2.09 6.11 ± 2.27 5.54 ± 2.0) 5.71 ± 2.27 6.31 ± 2.10
Pain group (n, %)
Moderate 117 (50.0) 65 (55.6) 52 (44.4) 17 (51.5) 62 (51.7) 38 (46.9)
Severe 77 (32.9) 34 (29.1) 43 (36.8) 7 (21.2) 38 (31.7) 32 (39.5)
Missing data 40 (17.1) 18 (15.4) 22 (18.8) 9 (27.3) 20 (16.7) 11 (13.6)
Polyneuropathy (n, %) 65 (27.8) 24 (20.5) 40 (34.2) 18 (54.4) 26 (21.7) 20 (24.7)
Post-herpetic neuralgia 
(n, %)
20 (8.5) 6 (5.1) 14 (12.0) 4 (12.1) 7 (5.8) 9 (11.1)
Peripheral nerve injury 
(n, %)
27 (11.5) 13 (11.1) 14 (12.0) 4 (12.1) 14 (11.7) 9 (11.1)
Complex regional pain 
syndrome (n, %)
65 (27.8) 38 (32.5) 27 (23.1) 4 (12.1) 43 (35.8) 18 (22.2)
Trigeminal neuropathy 
(n, %)
34 (14.5) 27 (23.1) 7 (6.0) 0 22 (18.3) 12 (14.8)
Central pain (n, %) 11 (4.7) 4 (3.4) 7 (6.0) 2 (6.1) 2 (1.7) 7 (8.6)
Other neuropathy (n, %) 13 (5.6) 5 (4.3) 8 (6.8) 1 (3.0) 6 (5.0) 6 (7.4)
Note: Values are given as mean ± single standard deviation, percentages or absolute values, respectively. Mean pain intensity was assessed using a numeric rating 
scale (NRS; 0 = no pain, 10 = worst pain imaginable).
Abbreviations: MH, mechanical hyperalgesia; SL, sensory loss; TH, thermal hyperalgesia.
aGenotyping of six DNA samples was not possible. 
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of the HTR2A rs6311 and rs6313 were in Hardy–Weinberg 
equilibrium for patients (p = .737 and p = .308) and controls 
(p = .758 and p = .831).
As HTR2A rs6311 and rs6313 genetic variants were almost 
in complete linkage disequilibrium (r2  =  0.97, D'  =  0.99), 
results of statistical analysis are only described in detail for 
rs6313. There were no significant differences in genotype 
distribution of the investigated SNVs between neuropathic 
pain patients, healthy controls and published data from 
1000 Genome Project (1000 Genomes Project Consortium 
et al., 2015; Sherry et al., 2001; Table 2).
3.2 | The somatosensory profile of 
neuropathic pain patients
To investigate possible effects of SNVs in HTR2A on the 
somatosensory function of neuropathic pain patients, we 
analysed the association between the selected SNVs and the 
standardized QST values of patients using a stepwise ap-
proach analysing (a) the effect on principal components of 
the QST parameters and (b) the effect on relevant single QST 
parameters.
3.3 | Principal component analysis
Principal component analysis revealed four major independ-
ent somatosensory components (Table 3) with the first prin-
cipal component (PC1, 21.05% of total variance) defined by 
thermal detection parameters (CDT, WDT, TSL) and some 
factor loading of heat pain (HPT). The second most impor-
tant principal component (PC2; 14.53% of total variance) 
was constituted by punctate mechanical nociception (MPT, 
MPS) as well as pain to light touch (DMA) and a smaller 
negative factor loading of temporal summation (WUR). PC3 
(13.13% of total variance) comprised thermal and blunt pres-
sure nociception, as well as pain summation (CPT, HPT, 
PPT, WUR) and PC4 (10.53% of total variance) was charac-
terized by mechanical detection parameters (MDT, VDT). As 
WUR was part of two principal components (PC2 and PC3), 
it was excluded for further calculation as being inconclusive 
and likely to blur selectivity. Due to the physiological mean-
ing of the different components, HPT was included in PC3 
(thermal/pressure nociception) rather than PC1 (thermal de-
tection). As shown previously, the shared variance of WDT 
and HPT relates to both sets of primary afferents express-
ing the TRPV1 receptor (Yarmolinsky et al., 2016). PC2 will 
be interpreted as reflecting CS as it comprises sensitivity to 
punctate stimuli (MPT, MPS) as well as pain to light touch 
(DMA).
Applying the dominant genetic model, both ANOVAs 
on PC1 (thermal detection) and on PC3 (thermal/pressure 
nociception) revealed a strong effect of cluster 1 versus 2 
(p <  .0001) and of sex (p =  .009, p <  .0001, respectively) 
as well as a significant cluster × sex interaction (p =  .001, 
p = .002). ANOVA on PC4 (mechanical detection) revealed 
only a strong effect of cluster 1 versus 2 (p < .001).
Only for PC2 (MPT, MPS, DMA = mechanical hyperal-
gesia/CS), three-way ANOVA revealed a significant trend 
towards an impact of the rs6313 genotype (F2.222 = 4.121, 
p  =  .017). Post hoc contrasts revealed only a marginally 
difference in the magnitude of PC2 comparing homozy-
gous variant carriers to homozygous wild-type carriers 
(+0.35 ± 0.15 vs. −0.11 ± 0.11, p = .052). There was no 
effect of cluster or sex, and no other significant interactions 
on PC2.
A closer look on PC2 magnitude revealed that the 
magnitude in heterozygous or homozygous variant allele 
carriers was almost identical (+0.22 ± 0.10 vs. +0.35 vs. 
0.16; Figure  2). We thus decided to apply the dominant 
genetic model, that is, comparing homozygous wild-type 
carriers and carriers of at least one variant allele. This ap-
proach disclosed a significant impact of rs6313 on PC2 
(F1,226 = 7.585, p = .006), but only a weak and non-signifi-
cant impact of cluster 1 versus 2 (F1,226 = 2.172, p = .142), 
and no impact of male versus female sex (F1,226 = 0.049, 
p =  .825). Notably, there was a cluster × genotype inter-
action on PC2 (F1,226  =  4.478, p  =  .035, no longer sig-
nificant after Bonferroni adjustment). In cluster 2 patients 
(relative loss of small and large fibre function), z values of 
wild-type carriers differed significantly from variant allele 
carriers (−0.34 ± 0.15 vs. +0.31 ± 0.11 vs., p < .001). In 
contrast, the difference in cluster 1 patients (mainly pre-
served function) was much smaller and did not reach sig-
nificance (+0.13 ± 0.15 vs. +0.20 ± 0.12, p > .50). Results 
F I G U R E  1  Allocation of the two-cluster to the three-cluster 
approach. The thermal hyperalgesia cluster (TH) mainly consists 
of cluster 1 patients (preserved sensory function). In contrast, the 
mechanical hyperalgesia cluster (MH) and the sensory loss cluster (SL) 
mainly consist of cluster 2 patients (sensory loss)
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of three-way ANOVAs of rs6313 genotype, clusters and 
sex as well as one-way ANOVAs for the different patient 
groups (all patients, cluster 1, cluster 2) on PC1-4 are 
shown in Table 4.
In summary, the PCA analysis revealed no significant 
impact of genotype on thermal detection, thermal/pressure 
hyperalgesia and mechanical detection; thus, the effect of 
genotype was specific for mechanical nociception.
3.4 | Effects of HTR2A rs6313 on single 
QST parameters
In the next step, the association of the rs6313 genotype to 
the somatosensory profile (z-scores or nominal values of the 
13 QST parameters) was investigated focusing on the single 
QST parameters of the relevant PC2, that is, MPS, MPT and 
DMA (Tables 5 and 6). In the entire patient cohort, patients 
with at least one variant allele exhibited an increased sensitiv-
ity to mechanical pain (MPS, +0.70 ± 0.11 vs. +0.28 ± 0.17, 
p =  .036; MPT, +0.57 ± 0.13 vs. +0.11 ± 0.16, p =  .032, 
no longer significant after Bonferroni adjustment) compared 
to wild-type carriers (Table  5). Differences became more 
distinct within the group of cluster 2 patients (sensory loss) 
with two groups of patients, that is, with and without ac-
companying mechanical hyperalgesia (MPS, p = .009; MPT, 
p = .002). The binary analysis of patients with abnormal sen-
sory response (z-scores above 1.96 or below −1.96) revealed 
that variant carriers in cluster 2 exhibited less frequently ab-
normal decreased sensitivity to mechanical pain compared 
to wild-type carriers (4% vs. 20%; p =  .016; Table 6). For 
DMA, no significant difference was observed neither in the 
entire patient cohort nor in cluster 2. In cluster 1, there was no 






MAF in neuropathic 
pain patients
MAF according to 
1000 Genomesa 




Note: There were no significant differences in genotype distribution between neuropathic pain patients, healthy 
controls and published data from 1000 Genome Project (1000 Genomes Project Consortium et al., 2015) 
assessed with chi-squared test.
Abbreviation: MAF, minor allele frequency.
a Allele frequencies in the European subpopulation according to the 1000 Genome Project (state 07/2019; 
https://www.ncbi.nlm.nih.gov/snp/). 
T A B L E  2  Minor allele frequencies 
(MAF) of each SNV in HTR2A in healthy 
controls, neuropathic pain patients and 
according to 1000 Genomes
QST parameters PC1 PC2 PC3 PC4
CDT 0.807a 0.046 0.090 0.086
WDT 0.837a −0.082 0.109 0.035
TSL 0.904a −0.057 0.037 0.087
CPT 0.238 0.044 0.666a 0.030
HPT 0.539a 0.135 0.497 0.062
PPT 0.022 0.214 0.691a 0.124
MPT −0.016 0.741a 0.093 0.203
MPS 0.045 0.841a 0.220 0.095
WUR −0.068 −0.566a 0.534a −0.032
MDT 0.300 0.137 0.015 0.687a 
VDT −0.034 0.098 0.129 0.782a 
DMA −0.130 0.450 0.398 −0.371
PHS −0.322 −0.059 −0.001 −0.247









Note: Factorial structure of QST data (after factor rotation using normalized VARIMAX).
aFactors exceeding factor loadings of ±0.50. 
T A B L E  3  Loading values of the 13 
QST parameters included in the principal 
component analysis (PCA) for the four 
principal sensory components (PC1-4)
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QST parameter of PC2. The somatosensory profile of the en-
tire patient cohort, cluster 1 and cluster 2 is shown in Figure 3.
3.5 | Gene-dosing effect of HTR2A rs6313
As there was an effect of HTR2A rs6313 on the mechani-
cal hyperalgesia component in particular in patients with a 
sensory loss, PC2 and the respective single QST parameters 
(MPT, MPS and DMA) were assessed for a gene-dose ef-
fect, defined as association of the number of variant alleles 
with z-scores, in cluster 2 (Figure 4). There was a significant 
gene-dose effect regarding PC2 (ß = 0.362, p =  .004) and 
MPT with an increase in MPT z-scores of ß = 0.648 from 
wild-type to heterozygous carriers and from heterozygous 
to variant carriers (p =  .001). While homozygous cluster 2 
variant carriers exhibited higher positive MPT z-scores than 
heterozygous carriers indicating hypersensitivity, wild-type 
carriers were characterized by negative z-scores indicating 
mechanical hyposensitivity. However, when looking at MPS 
and DMA only, there was no evidence for a gene-dose effect. 
Thus, the expression varied to either side for heterozygous 
versus homozygous variant carriers in the three QST param-
eters suggesting that a dominant genetic effect of the variant 
allele rather than gene-dosing describes the differences best.
3.6 | Sex-dependent analysis
To detect gender-dependent differences, statistical analysis was 
performed for male and female patients separately in a next 
step (data not shown). Genotype-associated somatosensory 
differences in male patients were similar to those of the entire 
patient cohort. In male patients, the variant allele was associ-
ated with an increased sensitivity to mechanical pain com-
pared to the wild-type (MPT, +0.84 ± 0.20 vs. +0.09 ± 0.24, 
p = .028). In cluster 2, variant carriers also exhibited a trend to-
wards an increased sensitivity to mechanical pain stimuli (MPT, 
+0.76 ± 0.27 vs. −0.46 ± 0.39, p = .015; MPS, +0.66 ± 0.23 
vs. −0.29 ± 0.28, p = .024) as well as less frequently abnormal 
decreased sensitivity to mechanical pain compared to wild-type 
carriers (5% vs. 29%, p = .017). By contrast, there were no sig-
nificant differences regarding female patients alone.
3.7 | Frequency of HTR2A rs6313 across 
three clusters
Although the current analysis was based on two distinct 
patient groups used in our previous genetic studies (Binder 
et al., 2011; Sachau et al., 2019), we reassessed our findings 
with respect to the recently published three-cluster solution 
(Baron et al., 2017) that had been validated in mechanism-
based human surrogate models (Vollert et al., 2018).
Differences in the genotype frequency (wild-type, hetero-
zygous, variant) were also calculated applying the recently 
published three-cluster solution (Table  7). In that cluster 
analysis, patients with sensory loss (cluster 2) are subdivided 
mainly into those with sensory loss only (SL) and those 
with additional mechanical hyperalgesia (MH; Figure  1). 
Consistent with the PCA shown above, the frequency of ho-
mozygous variant carriers was higher in MH patients than in 
SL patients (51% vs. 17%). In contrast, frequency of homozy-
gous wild-type carriers was highest in patients characterized 
F I G U R E  2  Effect of HTR2A rs6313 on the mechanical hyperalgesia component PC2 (MPT, MPS and DMA). (a) Heterozygous carriers and 
homozygous variant carriers were characterized by similar z values for PC2 with no significant differences overall. (b) In contrast, there was a 
significant difference when applying the dominant genetic model, that is, comparing homozygous wild-type carriers (CC) and carriers of at least 
one variant allele (CT + TT; p = .008). One-way ANOVA was performed, uncorrected p value: *p < .05, **p < .01
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by thermal hyperalgesia (cluster TH) and lowest in patients 
with sensory loss (cluster SL, 53% vs. 21%).
3.8 | An interaction of HTR2A rs6313 
genotype with the QST phenotype predicts 
levels of ongoing pain
The majority of patients (194/234) provided estimates of 
their levels of ongoing pain. They were analysed with the 
same three-way model of ANOVA that we had used for the 
analysis of the expression of the PC2 component of QST 
(Table 8). The three-way ANOVA explaining a total of 5.8% 
of variance revealed a complete absence of an overall differ-
ence in pain levels between clusters 1 and 2 (F1,186 = 0.007, 
p  =  .935) in line with the absence of a significant differ-
ence in pain between patients of cluster 1 and 2 (5.71 ± 0.21 
vs. 6.11 ± 0.21, p >  .20). Moreover, there was a weak but 
non-significant impact of sex and genotype (F1,186 = 3.203, 
p = .075 and F1,186 = 3.203, p = .135; respectively). However, 
T A B L E  5  Associations of HTR2A c.102C > T (rs6313) with somatosensory function reflected by QST parameters of the relevant PC2
Genotype N
MPT MPS DMAlog
z-score p valuea z-score p valuea Mean p valueb 
All patients
CC 81 0.11 ± 0.16 (1.43) .032(*) 0.28 ± 0.17 (1.50) .036 −0.70 ± 0.08 
(0.68)
.174
CT + TT 153 0.57 ± 0.13 (1.62) 0.70 ± 0.11 (1.42) −0.50 ± 0.07 
(0.84)
Cluster 1
CC 40 0.56 ± 0.19 (1.22) .838 0.65 ± 0.23 (1.48) .766 −0.81 ± 0.09 
(0.57)
.301
CT + TT 77 0.50 ± 0.19 (1.68) 0.73 ± 0.16 (1.39) −0.62 ± 0.08 
(0.72)
Cluster 2
CC 41 −0.34 ± 0.23 (1.50) .002* −0.09 ± 0.23 (1.45) .009* −0.60 ± 0.12 
(0.76)
.329
CT + TT 76 0.64 ± 0.18 (1.56) 0.66 ± 0.17 (1.45) −0.37 ± 0.11 
(0.94)
Note: Z-scores are given as arithmetic mean ± standard error of the mean (standard deviation).
Uncorrected p < .05 are marked in bold black, *significant after Bonferroni adjustment; (*)significant trend after Bonferroni adjustment.
Abbreviations: DMA, dynamic mechanical allodynia; MPS, mechanical pain sensation; MPT, mechanical pain threshold.
ap values for analysis of variance (ANOVA). 
bp values for Kruskal–Wallis test. 
T A B L E  6  Associations of HTR2A c.102C > T (rs6313) with frequencies of abnormal QST parameters of the relevant PC2
Genotype N
MPT MPS DMA
Loss Gain Loss Gain Gain
n (%) p value n (%) p value n (%) p value n (%) p value n (%) p value
All patients
CC 81 8 (9) .180 9 (11) .097 1 (1) 1.000 10 (12) .240 21 (26) .285
CT + TT 153 8 (5) 30 (20) 1 (0.7) 28 (18) 50 (33)
Cluster 1
CC 40 0 (0) .164 6 (15) .549 0 (0) 1.000 5 (13) .533 7 (18) .376
CT + TT 77 5 (6) 15 (19) 1 (1) 13 (17) 19 25)
Cluster 2
CT + TT 76 3 (4) 0.016* 15 (20) 0.107 0 (0) 0.350 15 (20) 0.301 31 (41) 0.481
Note: p values for chi-squared test or Fisher's exact test for n < 5.
Uncorrected p < .05 are marked in bold black, *significant after Bonferroni adjustment.
Abbreviations: DMA, dynamic mechanical allodynia; MPS, mechanical pain sensation; MPT, mechanical pain threshold.
   | 605SACHAU et Al.
there was a strong impact of a cluster × genotype interaction 
(F1,186 = 11.640, p ≤ .001), but no other significant interac-
tions (all p > .30, Table 8). Post hoc analysis revealed that 
pain levels were not different between wild-type and vari-
ant allele carriers in cluster 1 (6.11 ± 2.02 vs. 5.51 ± 2.12, 
p > .05). In contrast, ongoing pain in cluster 2 patients being 
variant allele carriers was >30% higher than in wild-type car-
riers (6.59 ± 2.32 vs. 5.05 ± 1.79, p < .001).
Since this pattern replicated the expression of the PC2 
QST component, we tested whether ongoing pain would be 
different if patients stratified for gain or loss in the PC2 com-
ponent. Patients with PC2 z values > 0 (PC2 gain, n = 104) 
presented with significantly higher pain ratings than patients 
with PC2 z values < 0 (PC2 loss, n = 90; 6.21 ± 0.20 vs. 
5.55  ±  0.24, p  <  .05). The PC2 QST component encom-
passed hyperalgesia to punctate stimuli (MPT and MPS) and 
pain to light touch (DMA) and is the main constituent of the 
mechanical hyperalgesia phenotype in the three-cluster ap-
proach (cluster MH). Most of these patients were members 
of cluster 2 (Figure  1). Indeed, patients of the mechanical 
hyperalgesia phenotype presented with significantly higher 
pain than patients of both other phenotypes, that is, sensory 
loss or thermal hyperalgesia (5.67 ± 0.20 vs. 6.31 ± 0.25, 
p  <  .05). Additionally, the magnitude of the PC2 z value 
was significantly correlated with the magnitude of ongo-
ing pain (r = 0.19, p <  .01). Moreover, the PC2 gain phe-
notype was significantly more frequent in the variant allele 
carriers (87/153  =  57%) than in the CC wild-type carriers 
(33/81 = 41%) as tested by chi square (χ2 = 5.51, p < .02).
4 |  DISCUSSION
The present study aimed at elaborating the influence of 
HTR2A genetic variants on the extent of sensory abnormali-
ties and ongoing pain intensity in patients with neuropathic 
pain. The rs6313 variant was associated with enhanced pin-
prick perception in neuropathic pain patients, in particular in 
subjects with a relative loss of small and large fibre function. 
These patterns were documented using principal somatosen-
sory components, the relevant QST parameters constituting 
this component, and two different approaches of cluster anal-
yses: two-cluster (Binder et  al.,  2011) versus three-cluster 
solution (Baron et al., 2017).
Previous studies have shown an involvement of HTR in 
nociceptive processing operating via spinal cord modulating 
facilitatory or inhibitory descending pathways. Of the seven 
known HTR subfamilies, HTR2 is thought to play an import-
ant role in spinal pain modulation. The HTR2A subtype is 
widely expressed in peripheral tissues, by dorsal root gan-
glion cells and primary afferent fibres but also in the central 
nervous system (Van Steenwinckel et  al.,  2009). Previous 
studies described a predominantly facilitatory role for 
HTR2A in acute nociceptive, inflammatory and neuropathic 
pain states via downstream activation of phospholipase C 
(Millan, 2002). In the spinal nerve injury model, serotoner-
gic descending pathways modulate PKCγ spinal interneurons 
through HTR2A activation leading to mechanical hyperalge-
sia (Artola et al., 2020), which is associated with spinal mor-
phological reorganization (Alba-Delgado et al., 2018). In an 
incision model, HTR2A mediated c-fos expression (Silveira 
et al., 2010) and downregulation of the chloride transporter 
KCC2 leading to a sensitizing shift of the anion equilibrium 
potential (Dong et al., 2016). While HTR2A agonists contrib-
ute to orofacial inflammatory hyperalgesia (Xue et al., 2020), 
selective HTR2A blockers and inhibitors of the HTR2A/
PSD95-binding complex are antihyperalgesic in neuropathic 
pain models (Aira et al., 2010; Rahman et al., 2011; Vogrig 
et al., 2013; Wang et al., 2012; Wattiez et al., 2017). However, 
an association of HTR2A genetic variants with neuropathic 
pain is largely unknown.
Our analysis showed no significant differences in the dis-
tribution of genetic variants between patients and healthy 
F I G U R E  3  Influence of HTR2A rs6313 on the somatosensory profile. (a) Somatosensory profile in the entire cohort of patients indicated 
that variant carriers (CT + TT; n = 153) exhibit an increased pinprick sensitivity compared to wild-type carriers (CC; n = 81), depicted by both 
threshold (MPT) and suprathreshold assessment (MPS). (b) In cluster 1, there was no significant association between HTR2A rs6313 genetic variant 
and a QST parameter. (c) In contrast, differences became more distinct when focusing on cluster 2 with significant differences for both MPT and 
MPS. For the somatosensory profile analysis of variance (ANOVA) and for dichotomized QST parameters (PHS, DMA), Kruskal–Wallis test 
were performed, uncorrected p values: *p < .05; **p < .01. Values are given as arithmetic mean and standard error of the mean. NRS, numeric 
rating scale; CDT, cold detection threshold; WDT, warm detection threshold; TSL, thermal sensory limen; CPT, cold pain threshold; HPT, heat 
pain threshold; PPT, pressure pain threshold; MPT, mechanical pain threshold; MPS, mechanical pain sensitivity; WUR, wind-up ratio; MDT, 
mechanical detection threshold; VDT, vibration detection threshold; DMA, dynamic mechanical allodynia; PHS, paradoxical heat sensation
(c)(b)(a)
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F I G U R E  4  Gene-dose effect of HTR2A rs6313 in cluster 2 patients. (a) Comparing all three genotypes, a gene-dose effect could be seen 
on PC2 (p = .004). (b) This effect was also shown for MPT alone (p = .001). While homozygous cluster 2 variant carriers (TT; n = 25) exhibited 
higher positive z-scores than heterozygous carriers (CT; n = 51) and wild-type carriers (CC; n = 41) exhibiting a negative z-score indicating 
mechanical hyposensitivity. (c and d) In contrast, there was no evidence for a gene-dose effect for MPS and DMA alone. Linear regression analysis 















CC 17 (21%) 43 (53%) 21 (26%) 81
CT 9 (8%) 64 (57%) 39 (35%) 112
TT 7 (17%) 13 (32%) 21 (51%) 41
Note: Absolute number and frequency (in round brackets) of each phenotype in wild-type, heterozygous and 
variant rs6313 carriers.
T A B L E  7  Frequency of HTR2A 
c.102C > T (rs6313) across the three 
clusters
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controls. The rs6313 variant was associated with differences 
in somatosensory function in neuropathic pain patients in a 
pathway-specific manner. Selective modulation of somato-
sensory processing by genetic variants was recently de-
scribed for genes coding SIGMAR1, TRP channels, μ-opioid 
receptor and cyclooxygenase 1 and 2 (Binder et al., 2011; Lee 
et al., 2006; Sachau et al., 2019).
In our study, the rs6313 variant was associated with the 
mechanical hyperalgesia principal component and respective 
single QST parameters. Variant carriers exhibited increased 
pinprick hyperalgesia than wild-type carriers, depicted by 
threshold and suprathreshold assessments. Mechanical pin-
prick hyperalgesia and dynamic mechanical allodynia are 
somatosensory hallmark signs of CS (Baron et  al.,  2012; 
Treede,  2016; von Hehn et  al.,  2012; Woolf,  2011). This 
phenomenon develops as a consequence of peripheral hyper-
activity leading to an increase in general excitability of noci-
ceptive and multi-receptive spinal cord dorsal horn projection 
neurons (wide-dynamic-range neurons; Baron et al., 2010). If 
CS is established, tactile stimuli become capable of activating 
spinal cord pain signalling neurons via Aβ-mechanoreceptors 
leading to pain to stroking light touch (dynamic mechanical 
allodynia) and enhanced activation by Aδ-mechanoreceptors 
leading to pinprick hyperalgesia (Henrich et  al.,  2015; 
LaMotte et al., 1991; Magerl et al., 2001; Simone et al., 1991; 
Ziegler et al., 1999). CS is modulated by descending systems 
from brainstem centres (Millan, 2002). Animal models sug-
gest that tonic activation of descending serotonergic pathways 
is involved in CS in neuropathic pain (Ossipov et al., 2010; 
Suzuki & Dickenson, 2005). In particular, HTR2A is thought 
to have a pro-nociceptive function on spinal nociceptive 
transmission and CS (Aira et al., 2010; Rahman et al., 2011; 
Vogrig et al., 2013; Wang et al., 2012; Wattiez et al., 2017). 
These observations may explain the differential effect of 
rs6313 on pinprick hyperalgesia as surrogate of CS. The 
rs6313 variant or variants closely linked to this synonymous 
variant might lead to a functional gain of HTR2A and could 
be considered as a relevant genotype facilitating CS.
These assumptions are supported by a study investigating 
the effect of SNVs in different genes on chronic pelvic pain, 
that is, interstitial cystitis (Cassão et al., 2019). Although no 
significant associations with disease prevalence or pain se-
verity were observed for rs6313, the rs6311 variant allele was 
associated with severe pain (results were not corrected for 
multiple testing). In our study, the promoter variant rs6311 
was in almost complete linkage disequilibrium to rs6313. 
Thus, genetic association of rs6313 is often attributed to 
functional consequences of rs6311 (Ruble et al., 2016). The 
rs6311 SNV is localized in the upstream promoter region 
of HTR2A and might influence transcription. It has been 
reported that the rs6311 variant increases HTR2A promoter 
activity via binding of specific transcription factors (Parsons 
et al., 2004). Thus, it might lead to an increased HTR2A ex-
pression in sensory neurons and facilitate pain generation. 
Other studies suggest a contradictory role for rs6311 (Myers 
et  al.,  2007), for example, a diminished protein expression 
by reduced extended 5'-UTR formation (Smith et al., 2013). 
The rs6313 genetic variant is a synonymous SNV localized 
in exon 1. Although no functional role has been described so 
far, rs6313 might influence RNA processing, that is, alterna-
tive splicing by affecting binding of splicing factors (Ruble 
et al., 2016). Nevertheless, functional studies are needed to 
clarify the molecular consequences of rs6311 and rs6313.
The principal component analysis revealed a signifi-
cant impact of rs6313 on mechanical nociception (PC2) in 
sensory loss patients (cluster 2). Accordingly, in cluster 2, 
the observed somatosensory differences for rs6313 became 
more distinct and the hyperalgesia could be considered 
as functional rescue from sensory loss, which was seen in 
homozygous wild-type carriers. In contrast, patients with 
mainly preserved sensory function (cluster 1) showed no 
significant association of rs6313 to any QST parameter. CS 
is influenced by hyperactivity in peripheral nociceptors and 
descending modulatory effects on spinal cord neurons (Baron 
et  al.,  2013). Thus, a differential effect of HTR2A variants 
on pinprick hyperalgesia might be more obvious in patients 
who are lacking the modulatory effect of peripheral activity 
(cluster 2).
Sex-dependent genetic influence on pain perception and 
psychiatric phenotypes is well known (Greenspan et al., 2007; 
Lebe et al., 2013). Lebe et al. identified a gender-dependent 
modulatory effect of rs6311 on depression and physical func-
tion in pain after lumbar disc surgery (Lebe et al., 2013). The 
variant allele was associated with higher depression scores 
in female patients confronted with pain but not in males. In 
our study, no relevant impact of gender has been identified 
in three-way ANOVA on PC2. Thus, observed differences 
between male and female patients are more likely linked to 
allocation of underlying diseases.
Applying a more refined stratification by the modified 
three-cluster analysis (Baron et  al.,  2017), frequency of 






1: c.102C > T (rs6313) CC 
versus CT + TT
1.186 2.253 .135
2: cluster 1 versus 2 1.186 0.007 .935
3: sex male versus female 1.186 3.203 .075
1 × 2 interaction 1.186 11.640 .001*
1 × 3 interaction 1.186 0.811 .369
2 × 3 interaction 1.186 0.098 .755
1 × 2 × 3 interaction 1.186 0.022 .883
a*significant p < .05 are marked in bold black. 
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rs6313 homozygous variant carriers was highest in patients 
with mechanical hyperalgesia (cluster MH), while frequency 
of homozygous wild-type carriers was highest in patients 
with thermal hyperalgesia (cluster TH). This underpins our 
results of an increased sensitivity to mechanical pain for the 
variant allele.
Finally, rs6313 explains a similar amount of variance for 
both evoked (pinprick) pain and ongoing spontaneous pain. 
The expression of gain in the PC2 somatosensory component 
interpreted as being related to the occurrence of CS was sig-
nificantly associated with more pain using various analyses. 
Thus, this is the first study showing that a change of somato-
sensory profile associated with a SNV can be tentatively in-
terpreted as evidence that CS can lead to higher pain owing 
to dysfunction of descending pain control.
As a limitation, there is no validation group provided in 
our study. Our results should be verified in a larger patient 
cohort, including also other genes that may interact with 
HTR2A in influencing the somatosensory phenotype of neu-
ropathic pain. However, patients were well-phenotyped using 
standardized QST. Although an impact of patients’ medi-
cation on QST results cannot be fully excluded, a recently 
published study in 1135 peripheral neuropathic pain patients 
suggests no significant impact of drugs on sensory profiles 
(Baron et al., 2017). Since phenotypical characterization of 
healthy controls was not performed in this study, the influ-
ence HTR2A variants on the somatosensory function in gen-
eral could not be determined. Due to the small sample size, 
subgroup analyses of underlying disease entities were not 
performed. However, the individual somatosensory profile is 
thought to reflect the underlying pain-generating mechanisms 
better than disease entities. Improvement of neuropathic 
pain therapy includes the development of drugs selectively 
targeting these mechanisms (Baron et  al.,  2017; Binder & 
Baron, 2015; Binder et al., 2011). The present study focused 
on the concept of mechanism-based therapy by analysing dif-
ferent subgroups of patients.
In summary, our study suggests that the genetic variant 
HTR2A rs6313 and the linked variant rs6311 increase the 
progress of pinprick hyperalgesia as surrogate of CS in neu-
ropathic pain patients. These effects seem to depend on the 
somatosensory phenotype and is mainly seen in loss of pe-
ripheral afferent small and large fibre function. Thus, our re-
sults present a promising avenue for future drug development 
and might help to realize the concept of mechanism-based 
therapy.
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